/
ARAY
$0.26-$0.00 (-1.85%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$31.5M
119M shares
52-week range
$0.25 – $2.10
1% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.51%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-4.29
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $404.9M | $418.8M | $382.9M | $396.3M | $429.9M | $447.6M | $446.6M | $458.5M |
| Cost of revenue | $243.2M | $256.1M | $233.2M | $236.8M | $270.0M | $293.6M | $303.6M | $311.5M |
| Gross profit | $161.7M | $162.7M | $149.7M | $159.5M | $160.0M | $154.0M | $142.9M | $147.0M |
| Gross margin | 39.9% | 38.8% | 39.1% | 40.3% | 37.2% | 34.4% | 32.0% | 32.1% |
| R&D | $57.3M | $56.5M | $49.8M | $52.7M | $57.8M | $57.1M | $49.7M | $47.9M |
| Operating income | −$3.8M | −$9.9M | $12.5M | $22.2M | $8.1M | $2.4M | $504.0K | $7.8M |
| EBITDA | $1.7M | $11.1M | $31.3M | $18.7M | $11.6M | $8.4M | $5.7M | $20.2M |
| Net income | −$23.9M | −$16.4M | $3.8M | −$6.3M | −$5.3M | −$9.3M | −$15.5M | −$1.6M |
| Net margin | -5.9% | -3.9% | 1.0% | -1.6% | -1.2% | -2.1% | -3.5% | -0.3% |
| EPS (diluted) | -0.28 | -0.19 | 0.04 | -0.07 | -0.06 | -0.10 | -0.16 | -0.02 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $407M | $-0.41 | $-0.41–$-0.41 | 1 |
| 2027 | $413M | $-0.24 | $-0.24–$-0.24 | 1 |
| 2028 | $423M | $-0.14 | $-0.14–$-0.14 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.00
Price
$0.26
Implied upside
+671%
Peer comparison
Accuray Incorporated
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
www.accuray.com- Employees
- 990
- IPO / List date
- Feb 8, 2007
- HQ
- MADISON, WI
Held by traders on TradeandTell
No one on the platform currently holds ARAY.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 2,290,984 | $889.1K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ARAY yet.
